

10/009809 #5

10 APR 2002

26 APR 2002

SEQUENCE LISTING

<110> Eisenberg, Ronit
Raz, Tamar

<120> Novel Anti-Allergic Agents

<130> 24025-501 NATL

<140> 10/009,809

<141> 2000-06-14

<150> PCT/IL00/00346

<151> 2000-06-14

<150> IL 130526

<151> 1999-06-17

<160> 21

<170> PatentIn Ver. 2.1

<210> 1

<211> 10

<212> PRT

<213> Homo sapiens

<400> 1

Lys Asn Asn Leu Lys Glu Cys Gly Leu Tyr
1 5 10

<210> 2

<211> 10

<212> PRT

<213> Homo sapiens

<400> 2

Lys Asn Asn Leu Lys Asp Cys Gly Leu Phe
1 5 10

<210> 3

<211> 16

<212> PRT

<213> Homo sapiens

<400> 3

Ala Ala Val Ala Leu Leu Pro Ala Val Leu Leu Ala Leu Ala Pro
1 5 10 15

<210> 4

<211> 15

<212> PRT

<213> Homo sapiens

<400> 4
Val Thr Val Leu Ala Leu Gly Ala Leu Ala Gly Val Gly Val Gly
1 5 10 15

<210> 5
<211> 16
<212> PRT
<213> Drosophila acanthoptera

A1 <400> 5
Arg Gln Pro Lys Ile Trp Phe Pro Asn Arg Arg Lys Pro Trp Lys Lys
1 5 10 15

<210> 6
<211> 25
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic Peptide

<400> 6
Val Thr Val Leu Ala Leu Gly Ala Leu Ala Gly Val Gly Val Gly Lys
1 5 10 15

Asn Asn Leu Lys Glu Cys Gly Leu Tyr
20 25

<210> 7
<211> 26
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic Peptide

<400> 7
Ala Ala Val Ala Leu Leu Pro Ala Val Leu Leu Ala Leu Leu Ala Pro
1 5 10 15

Lys Asn Asn Leu Lys Glu Cys Gly Leu Tyr
20 25

<210> 8
<211> 26
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic Peptide

<220>
 <221> VARIANT
 <222> (1)..(26)
 <223> N-terminal amino acid is succunylated

<400> 8
 Ala Ala Val Ala Leu Leu Pro Ala Val Leu Leu Ala Leu Ala Pro
 1 5 10 15

Lys Asn Asn Leu Lys Glu Cys Gly Leu Tyr
 20 25

<210> 9
 <211> 26
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic Peptide

<220>
 <221> VARIANT
 <222> (7)
 <223> A bond exists between the side chain of Lys and the C-terminus of the peptide.

<400> 9
 Ala Ala Val Ala Leu Leu Pro Ala Val Leu Leu Ala Leu Leu Ala Pro
 1 5 10 15

Lys Asn Asn Leu Lys Glu Cys Gly Leu Tyr
 20 25

<210> 10
 <211> 26
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic Peptide

<400> 10
 Arg Gln Pro Lys Ile Trp Phe Pro Asn Arg Arg Lys Pro Trp Lys Lys
 1 5 10 15

Lys Asn Asn Leu Lys Glu Cys Gly Leu Tyr
 20 25

<210> 11
 <211> 25
 <212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic Peptide

<400> 11

Val Thr Val Leu Ala Leu Gly Ala Leu Ala Gly Val Gly Val Gly Lys
1 5 10 15

Glu Asn Leu Lys Asp Cys Gly Leu Phe
20 25

<210> 12

<211> 26

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic Peptide

<400> 12

Ala Ala Val Ala Leu Leu Pro Ala Val Leu Leu Ala Leu Leu Ala Pro
1 5 10 15

Lys Glu Asn Leu Lys Asp Cys Gly Leu Phe
20 25

<210> 13

<211> 26

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic Peptide

<400> 13

Arg Gln Pro Lys Ile Trp Phe Pro Asn Arg Arg Lys Pro Trp Lys Lys
1 5 10 15

Lys Glu Asn Leu Lys Asp Cys Gly Leu Phe
20 25

<210> 14

<211> 26

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic Peptide

<400> 14

Ala Ala Val Ala Leu Leu Pro Ala Val Leu Leu Ala Leu Leu Ala Pro
1 5 10 15

Lys Asn Asn Leu Lys Asp Cys Gly Leu Phe
20 25

<210> 15

<211> 26

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
Peptide

<220>

<221> VARIANT

<222> (1)..(26)

<223> N-terminal amino acid is succinylated

<400> 15

Ala Ala Val Ala Leu Leu Pro Ala Val Leu Leu Ala Leu Leu Ala Pro
1 5 10 15

Lys Glu Asn Leu Lys Asp Cys Gly Leu Phe
20 25

<210> 16

<211> 27

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
Peptide

<400> 16

Lys Ala Ala Val Ala Leu Leu Pro Ala Val Leu Leu Ala Leu Leu Ala
1 5 10 15

Pro Lys Asn Asn Leu Lys Asp Cys Gly Leu Phe
20 25

<210> 17

<211> 27

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
Peptide

<400> 17

Lys Ala Ala Val Ala Leu Leu Pro Ala Val Leu Leu Ala Leu Leu Ala
 1 5 10 15

Pro Lys Asn Asn Leu Lys Glu Cys Gly Leu Tyr
 20 25

<210> 18
 <211> 23
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 Peptide

<400> 18
 Ala Ala Val Ala Leu Leu Pro Ala Val Leu Leu Ala Leu Leu Ala Pro
 1 5 10 15

Leu Lys Glu Cys Gly Leu Tyr
 20

<210> 19
 <211> 23
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 Peptide

<400> 19
 Ala Ala Val Ala Leu Leu Pro Ala Val Leu Leu Ala Leu Leu Ala Pro
 1 5 10 15

Leu Lys Asp Cys Gly Leu Phe
 20

<210> 20
 <211> 26
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 Peptide

<400> 20
 Ala Ala Val Ala Leu Leu Pro Ala Val Leu Leu Ala Leu Leu Ala Pro
 1 5 10 15

Lys Asn Asn Leu Lys Glu Ser Gly Leu Tyr
 20 25

<210> 21
<211> 26
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Peptide

<220>
<221> VARIANT
<222> (1)..(2)
<223> Ala in D/L configuration

<400> 21
Ala Ala Val Ala Leu Leu Pro Ala Val Leu Leu Ala Leu Leu Ala Pro
1 5 10 15

Lys Asn Asn Leu Lys Glu Cys Gly Leu Tyr
20 25

209240" 5086000F

A¹
Cone